Drug intelligence / Profile preview

18F FMD

Development stage: Preclinical
Lead developer: Ashvattha Therapeutics
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

18F FMD is a dendrimer-based diagnostic imaging agent developed by Ashvattha Therapeutics. It functions as a diagnostic imaging enhancer, intended for use in Positron Emission Tomography (PET) imaging. The drug is currently undergoing clinical trials for Multiple Sclerosis and preclinical trials for other neurological disorders.

Beyond the preview

Go deeper on 18F FMD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 18F FMD.

Explore the full profile